Oct 29 (Reuters) - Intellia Therapeutics ( NTLA ) said
on Wednesday that the U.S. Food and Drug Administration has
placed a clinical hold on its two late-stage trials testing an
experimental gene-editing therapy for a rare disease that can
damage the heart and nerves.